Bladder Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Bladder Cancer Information Center has current, evidence-based information for you. Get the facts about bladder cancer early detection, treatment, and survivorship, and stay up to date with ongoing bladder cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Bladder Cancer Community is the leading Social Media Application for Bladder Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Bladder cancer will be diagnosed in approximately 77,000 people in the United States... Tecentriq® Approved for Bladder Cancer
The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab)... Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer
The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity...
Michael O’Donnell, MD Director of Urologic Oncology, Department of Urology University... What You Should Know About Bladder Cancer
Michael O’Donnell, MD Director of Urologic Oncology University of Iowa Hospitals... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious...
Bladder Cancer Management
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer... Pay it Forward
Survivors become peer mentors to newly diagnosed women and offer experience, insight,...
Bladder Cancer Clinical Trials
E1804 – Phase II Trial of Sorafenib (BAY-43) (IND69896;NSC 724772) in Patients with Advanced Urothelial Cancer
A-1-08 – Phase II Single-arm, Single-Agent Multicenter, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial Cancer.
GU07 – A Phase II Trial Of Paclitaxel, Carboplatin, And Gemcitabine In The Treatment of Advanced Transitional Cell Carcinoma of The Urothelial Tract.